This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Field, A. E.
Right arrow Articles by Mosser, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Field, A. E.
Right arrow Articles by Mosser, D. M.

 Previous Article  |  Next Article 

Infection and Immunity, June 2007, p. 3140-3149, Vol. 75, No. 6
0019-9567/07/$08.00+0     doi:10.1128/IAI.00160-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Reduced Pathology following Infection with Transgenic Leishmania major Expressing Murine CD40 Ligand{triangledown}

Ann E. Field, Sagie Wagage, Sean M. Conrad, and David M. Mosser*

Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland 20742

Received 30 January 2007/ Returned for modification 9 March 2007/ Accepted 23 March 2007

Leishmanization is the inoculation of live Leishmania into the host to vaccinate against subsequent infections. This approach has been largely discontinued due to safety concerns. We have previously shown that combining CD40 ligand (CD40L) with Leishmania antigen preferentially induces a type 1 immune response and provides some protection to vaccinated mice (G. Chen, P. A. Darrah, and D. M. Mosser, Infect. Immun. 69:3255-3263, 2001). In the present study, we developed transgenic L. major organisms which express and secrete the extracellular portion of CD40L (L. major CD40LE). We hypothesized that these organisms would be less virulent but more immunogenic than wild-type organisms and therefore be more effective at leishmanization. Transgenic parasites expressing CD40L mRNA and protein were developed. BALB/c mice infected with these parasites developed significantly smaller lesions containing fewer parasites than animals infected with wild-type organisms. Infection of resistant C57BL/6 mice with low doses of transgenic parasites induced a significant amount of protection against subsequent high-dose infection with wild-type organisms. These results demonstrate that transgenic organisms expressing CD40L are less virulent than wild-type organisms while retaining full immunogenicity.

* Corresponding author. Mailing address: University of Maryland, 1103 Microbiology Building (Building 231), College Park, MD 20742. Phone: (301) 314-2954. Fax: (301) 314-9489. E-mail: dmosser{at}umd.edu

{triangledown} Published ahead of print on 2 May 2007.

Editor: W. A. Petri, Jr.

Infection and Immunity, June 2007, p. 3140-3149, Vol. 75, No. 6
0019-9567/07/$08.00+0     doi:10.1128/IAI.00160-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Soong, L. (2008). Modulation of Dendritic Cell Function by Leishmania Parasites. J. Immunol. 180: 4355-4360 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»